Skip to main content

Table 1 Prognostic studies in breast cancer looking at HIF-1α and HIF-2α overexpression detected via immunohistochemistry

From: Gene expression and hypoxia in breast cancer

Group Tumor type Number of cases Overall outcome Association of marker on multivariate analysis
Schindl et al.
[90]
LN+ early BC 206 Unfavorable prognosis for HIF-1α. HIF-2α not assessed DFS HR = 1.4; P = 0.001
Trastour et al.
[91]
Early BC 132 Unfavorable prognosis for HIF-1α. HIF-2α not assessed DFS HR = 4.2; P < 0.001
Bos et al. [92] Stage 1-2 early BC 150 Trend toward unfavorable prognosis for HIF-1α (significant for LN- patients).
HIF-2α not assessed
OS HR = 2.16; P = 0.12
DFS HR = 1.67; P = 0.12
Generali et al. [36] T2-4 N0-1 early BC 187 Unfavorable prognosis for CAIX. Treatment response for HIF-1α. HIF-2α not assessed DFS (CAIX) HR = NR; P = 0.02
Clinical response to treatment (HIF-1α): P < 0.05
Gruber et al. [93] LN+ early BC 77 Trend toward unfavorable prognosis for HIF-1α. HIF-2α not assessed OS HR = 2.66; P = 0.09
DFS HR = 1.68; P = 0.30
Yamamoto et al. [94] Early BC 171 Unfavorable prognosis for HIF-1α. HIF-2α not assessed OS HR = 2.15; P = 0.02
DFS HR = 1.59; P = 0.02
Jubb et al. [3] Meta-analysis 923 Trend toward unfavorable prognosis for HIF-1α. HIF-2α not assessed OS HR = 1.80
(95% CI 1.32 to 2.47)
Schoppmann et al. [95] LN+ early BC 119 Unfavorable prognosis for HIF-1α OS HR = NR; P = 0.03
DFS HR = NR; P = 0.04
Vleugel et al.
[21]
Early BC 166 Unfavorable prognosis for HIF-1α DFS HR = 2.23; P = 0.01
Dales et al. [96] Early BC 745 Unfavorable prognosis for HIF-1α OS HR = NR; P = 0.030
DFS HR = NR; P = 0.158
Helczynska et al. [97] Early BC 512 Unfavorable prognosis for HIF-2α. No significant association for HIF-1α BCSS (HIF-2α) HR = 2.3; P = 0.003
DFS (HIF-2α) HR = 1.6; P = 0.03
  1. BC, breast cancer; BCSS, breast cancer-specific survival; CI, confidence interval; LN+, lymph node positive; LN-, lymph node negative; DFS, disease free survival; HR, hazard ratio; NR, not reported; OS, overall survival.